Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R SzydloMary M Horowitz

Abstract

To compare outcomes of bone marrow transplants for leukemia from HLA-identical siblings, haploidentical HLA-mismatched relatives, and HLA-matched and mismatched unrelated donors. A total of 2,055 recipients of allogeneic bone marrow transplants for chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), and acute lymphoblastic leukemia (ALL) were entered onto the study. Transplants were performed between 1985 and 1991 and reported to the International Bone Marrow Transplant Registry (IBMTR). Donors were HLA-identical siblings (n = 1,224); haploidentical relatives mismatched for one (n = 238) or two (n = 102) HLA-A, -B, or -DR antigens; or unrelated persons who were HLA-matched (n = 383) or mismatched for one HLA-A, -B, or -DR antigen (n = 108). HLA typing was performed using serologic techniques. Transplant-related mortality was significantly higher after alternative donor transplants than after HLA-identical sibling transplants. Among patients with early leukemia (CML in chronic phase or acute leukemia in first remission), 3-year transplant-related mortality (+/-SE) was 21% +/- 2% after HLA-identical sibling transplants and greater than 50% after all types of alternative donor transplants studied. Among patients ...Continue Reading

Citations

Nov 26, 1998·The New England Journal of Medicine·P RubinsteinC E Stevens
Apr 14, 2000·Cancer Control : Journal of the Moffitt Cancer Center·R A Saez
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K T GodderP J Henslee-Downey
May 22, 2001·Bone Marrow Transplantation·J M Rowe, H M Lazarus
Mar 13, 2001·Bone Marrow Transplantation·M J Laughlin
Apr 20, 2002·Blood·Nancy BuninUNKNOWN National Marrow Donor Program Working Group
Mar 1, 2002·The New England Journal of Medicine·David G Savage, Karen H Antman
Nov 7, 2002·Bone Marrow Transplantation·P DugganUNKNOWN Alberta Blood and Bone Marrow Transplant Program
Aug 6, 2008·Bone Marrow Transplantation·H J Symons, E J Fuchs
Jun 12, 2010·Annals of the New York Academy of Sciences·Katia PerruccioAndrea Velardi
Jun 10, 2010·Bone Marrow Transplantation·N VenepalliB N Savani
Sep 18, 2010·Blood·Jeffrey J Molldrem, Gheath Alatrash
Apr 11, 2015·Blood·Ephraim J Fuchs
Aug 12, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yvette L KasamonRichard J Jones
Nov 5, 2016·Blood·Renato CunhaUNKNOWN Eurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of the European Society for Blood and Marrow Tra
Jun 20, 2017·Statistical Methods in Medical Research·Haolun Shi, Guosheng Yin

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.